

APPENDIX VII

STATUTORY AND GENERAL INFORMATION

A. FURTHER INFORMATION ABOUT OUR GROUP

1. Establishment of Our Company

Our Company was established as a limited liability company in the PRC on May 22, 2020 and was converted into a joint stock limited company on November 26, 2025. Our Company has established a place of business in Hong Kong at Room 1901, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong and has been registered as a non-Hong Kong company under Part 16 of the Companies Ordinance on January 8, 2026. Ms. Li Yee Ching (李漪澄女士) has been appointed as our authorized representative for acceptance of service of process and notices in Hong Kong whose correspondence address is the same as our place of business in Hong Kong.

As our Company is established in the PRC, our corporate structure and Articles of Association are subject to the relevant laws and regulations of the PRC. A summary of the relevant provisions of our Articles of Association is set out in “Appendix VI — Summary of Articles of Association.”

2. Changes in the Share Capital of Our Company

Save as disclosed in “History, Development and Corporate Structure,” there has been no change in the share capital of our Company within the two years immediately preceding the date of this document.

3. Change in the Share Capital of Our Subsidiaries

A summary of the corporate information and the particular of our subsidiary is set out in the Accountants’ Report. There has been no change in the share capital of our subsidiary within the two years preceding the date of this document.

4. Resolutions of Our Shareholders

Pursuant to the resolutions passed at a duly convened general meeting of our Shareholders held on January 5, 2026, our Shareholders resolved that, among others:

- (a) the issuance of H Shares with a nominal value of RMB1.00 each and such H Shares being [REDACTED] on the Stock Exchange;
- (b) the number of H Shares to be issued pursuant to the [REDACTED], and the grant to the [REDACTED] of the [REDACTED] of not more than 15% of the number of H Shares initially available under the [REDACTED];
- (c) subject to the filing procedure with the CSRC, upon the completion of the [REDACTED], [REDACTED] Domestic Shares held by existing Shareholders will be converted into H Shares on a one-for-one basis;
- (d) subject to the completion of the [REDACTED], the grant of a general mandate to our Board to allot, issue and deal with Shares at any time within a period up to the date of the conclusion of the next annual general meeting of the Shareholders or the date on which the Shareholders pass a special resolution to revoke or change such mandate, whichever is earlier, upon such terms and conditions and for such purposes and to such persons as our Board in their absolute discretion deem fit, and to make necessary amendments to the Articles of Association, provided that, the number of Shares to be issued shall not exceed [REDACTED]% of the number of the Shares in issue (excluding any H Shares issued pursuant to the [REDACTED]) as at the [REDACTED];

APPENDIX VII STATUTORY AND GENERAL INFORMATION

- (e) subject to the completion of the [REDACTED], the adoption of the Articles of Association which shall become effective on the [REDACTED], and authorization to our Board to amend the Articles of Association to the extent necessary for the purpose of the [REDACTED]; and
- (f) authorization of our Board or its authorized individual(s) to deal with all matters relating to the [REDACTED] and the [REDACTED].

5. Restriction on Share Repurchase

For details of the restrictions on share repurchase by our Company, see “Appendix VI — Summary of Articles of Association.”

B. FURTHER INFORMATION ABOUT OUR BUSINESS

1. Summary of Material Contract

We [have] entered into the following contract (not being contract entered into in the ordinary course of business) within the two years immediately preceding the date of this document that is or may be material:

- (a) the [REDACTED].

2. Intellectual Property Rights

(a) Trademarks

As of the Latest Practicable Date, we had registered the following trademarks which we considered to be material to our business.

No.	Trademark Design	Registration No.	Expiry Date	Classification	Place of Registration
1 . .	邦顺制药	63002549	December 6, 2032	Class 42	PRC
2 . .		62997944	September 6, 2032	Class 5	PRC
3 . .	BIOSUN PHARMA	63010117	October 27, 2032	Class 42	PRC
4 . .		63005621	September 6, 2032	Class 42	PRC
5 . .	BIOSUN PHARMA	63002500	November 13, 2032	Class 5	PRC
6 . .	顺安明	72303259	December 6, 2033	Class 5	PRC
7 . .	邦恪明	72303262	December 6, 2033	Class 5	PRC
8 . .	邦济瑞	72303263	December 6, 2033	Class 5	PRC
9 . .	邦瑞顺	72303261	December 6, 2033	Class 5	PRC
10 .	邦纤复	72303258	December 6, 2033	Class 5	PRC

APPENDIX VII STATUTORY AND GENERAL INFORMATION

No.	Trademark Design	Registration No.	Expiry Date	Classification	Place of Registration
11 .	邦济明	72303265	December 6, 2033	Class 5	PRC
12 .	邦裕明	72303260	December 6, 2033	Class 5	PRC

(b) Patents

As of the Latest Practicable Date, we had registered the following patents which we considered to be material to our business.

No.	Patent Name	Patent Type	Inventor	Owner	Applicant	Corresponding Core Product or pipeline product	Registration No.	Application Date	Place of Registration
1 . .	Phenylaminopyrimidine derivatives and their use in preparation of drugs for resisting cancers (苯胺嘧啶衍生物及其在製備抗惡性腫瘤藥物中的用途)	Invention	Yin Jianming; Li Bangliang; Lyu Yubin	Hangzhou Bangshun Pharmaceutical Co., Ltd.	Hangzhou East China Pharmaceutical Group New Drugresearch Institute Co., Ltd.; Yin Jianming	CX510	ZL201510405448.6	July 9, 2015	PRC
2 . .	Pyrrolopyrimidine five-membered azacyclic derivative and application thereof (吡咯嘧啶五元氮雜環衍生物及其應用)	Invention	Yin Jianming; Lyu Yubin; Li Bangliang	Hangzhou Bangshun Pharmaceutical Co., Ltd.	Hangzhou East China Pharmaceutical Group New Drug Research Institute Co., Ltd.; Yin Jianming	OB756	ZL201710055590.1	January 25, 2017	PRC
3 . .	Imidazopyridinamine phenyl derivative and use thereof (一種咪唑吡嗪胺苯基衍生物及其用途)	Invention	Yin Jianming; Lyu Yubin; Li Bangliang	Hangzhou Bangshun Pharmaceutical Co., Ltd.	Hangzhou East China Pharmaceutical Group New Drug Research Institute Co., Ltd.; Yin Jianming	CX1440	ZL201710519104.7	June 30, 2017	PRC
4 . .	Bruton's tyrosine kinase inhibitors (布魯頓酪氨酸激酶抑制劑)	Invention	Liao Xibin; Lyu Yubin	Hangzhou Bangshun Pharmaceutical Co., Ltd.	Hangzhou Bangshun Pharmaceutical Co., Ltd.	CX01	ZL202080009929.4	January 17, 2020	PRC
5 . .	NLRP3 inhibitors (NLRP3抑制劑)	Invention	Yang Xin; Cui Rong; Zheng Mei; Yin Jianming; Lyu Yubin	Hangzhou Bangshun Pharmaceutical Co., Ltd.	Hangzhou Bangshun Pharmaceutical Co., Ltd.	CX08	ZL202211376729.X	November 4, 2022	PRC
6 . .	Substituted pyrazolo [1,5-a] pyrimidine compounds and uses thereof (取代的吡唑並[1,5-a]嘧啶化合物及其用途)	Invention	Yang Xin; Cui Rong; Zhang Hualing; Kong Xiangwen; Bao Yuehua; Hu Zuyao	Hangzhou Bangshun Pharmaceutical Co., Ltd.	Hangzhou Bangshun Pharmaceutical Co., Ltd.	ND01	ZL202110844787.X	July 26, 2021	PRC
7 . .	Pim kinase inhibitor (PIM激酶抑制劑)	Invention	Yang Xin; Cui Rong; Yin Jianming; Zheng Mei; Chen Nanyu; Lyu Yubin	Hangzhou Bangshun Pharmaceutical Co., Ltd.	Hangzhou Bangshun Pharmaceutical Co., Ltd.	CX03	ZL202210996688.8	January 29, 2022	PRC

APPENDIX VII STATUTORY AND GENERAL INFORMATION

No.	Patent Name	Patent Type	Inventor	Owner	Applicant	Corresponding Core Product or pipeline product	Registration No.	Application Date	Place of Registration
8 . .	Crystal form of Pyrrolopyrimidine five-membered azacyclic compound (吡咯嘧啶五元氮雜環化合物的晶型)	Invention	Yin Jianming; Chen Nanyu; Hao Wende; Zhuge Dingjuan; Zheng Mei	Hangzhou Bangshun Pharmaceutical Co., Ltd.	Hangzhou Bangshun Pharmaceutical Co., Ltd.	OB756	ZL202111268081.X	October 29, 2021	PRC
9 . .	Pim kinase inhibitor (PIM激酶抑制剂)	Invention	Yang Xin; Cui Rong; Yin Jianming; Zheng Mei; Chen Nanyu; Lyu Yubin	Hangzhou Bangshun Pharmaceutical Co., Ltd.	Hangzhou Bangshun Pharmaceutical Co., Ltd.	CX03	ZL202210112402.5	January 29, 2022	PRC
10 . .	Selective ROCK2 kinase inhibitors (選擇性 ROCK2激酶抑制剂)	Invention	Yang Xin; Zhuge Dingjuan; Bao Yuehua; Zheng Mei; Yin Jianming; Lyu Yubin	Hangzhou Bangshun Pharmaceutical Co., Ltd.	Hangzhou Bangshun Pharmaceutical Co., Ltd.	CX02	ZL202210214601.7	March 4, 2022	PRC
11 . .	Anti-siglec15 antibody, preparation method therefor and use thereof (抗Siglec15抗體及其製備方法和用途)	Invention	Li Chaohui; Liu Wenhui; Fang Jie; Wu Min; Liu Wenhui; Lyu Yubin	Hangzhou Bangshun Pharmaceutical Co., Ltd.	Hangzhou Bangshun Pharmaceutical Co., Ltd.	CXS004	ZL202210406286.8	April 18, 2022	PRC
12 . .	Preparation of anti-CD24 antibody and use thereof (抗CD24抗體的製備及其用途)	Invention	Li Chaohui; Liu Wenhui; Xie Zhangming; Wu Min; Fang Jie; Zhang Qian; Fang Hedi; Lyu Yubin	Hangzhou Bangshun Pharmaceutical Co., Ltd.	Hangzhou Bangshun Pharmaceutical Co., Ltd.	CXS008	ZL202310111450.7	February 14, 2023	PRC
13 . .	ALK2 kinase inhibitor (ALK2激酶抑制剂)	Invention	Yang Xin; Cui Rong; Wen Qiaodong; Yin Jianming; Zheng Mei; Lyu Yubin	Hangzhou Bangshun Pharmaceutical Co., Ltd.	Hangzhou Bangshun Pharmaceutical Co., Ltd.	CX04	ZL202310387713.7	April 12, 2023	PRC
14 . .	IRAK kinase inhibitors (IRAK激酶抑制剂)	Invention	Lu Jian; Qing Yali; Huang Xuehui; Ren Yueying; Song Na; Yang Xin; Wen Qiaodong; Zhuge Dingjuan; Zheng Mei; Yin Jianming; Lyu Yubin	Hangzhou Bangshun Pharmaceutical Co., Ltd.	Hangzhou Bangshun Pharmaceutical Co., Ltd.	CX05	ZL202310620527.3	May 30, 2023	PRC
15 . .	Imidazopyrazinamine phenyl derivative and use thereof	Invention	Yin Jianming; Lyu Yubin; Li Bangliang	Hangzhou Bangshun Pharmaceutical Co., Ltd.	Hangzhou Sanyintai Pharmaceutical Technology Co., Ltd.; Yin Jianming	CX1440	US10640512B2	June 29, 2017	the U.S.

APPENDIX VII STATUTORY AND GENERAL INFORMATION

No.	Patent Name	Patent Type	Inventor	Owner	Applicant	Corresponding Core Product or pipeline product	Registration No.	Application Date	Place of Registration
16	Pyrrolopyrimidine five-membered azacyclic derivative and application thereof	Invention	Yin Jianming; Lyu Yubin; Li Bangliang	Hangzhou Bangshun Pharmaceutical Co., Ltd.	Hangzhou Huadong Medicine Group Biopharmaceutical Co. Ltd; Yin Jianming	OB756	US10822339B2	January 25, 2017	the U.S.
17	Pyrrolopyrimidine five-membered azacyclic derivative and application thereof	Invention	Yin Jianming; Lyu Yubin; Li Bangliang	Hangzhou Bangshun Pharmaceutical Co., Ltd.	Hangzhou Huadong Medicine Group Biopharmaceutical Co. Ltd; Yin Jianming	OB756	JP6770580B2	January 25, 2017	Japan

(c) Copyright

As of the Latest Practicable Date, we had registered the following copyright which we considered to be material to our business.

No.	Copyright	Registration Number	Type	Registration Date	Place of Registration
1.	Biosun Pharma Logo	國作登字-2022-F-10089442	Artistic	April 27, 2022	PRC

(d) Domain Name

As of the Latest Practicable Date, we had registered the following internet domain name which we considered to be material to our business:

No.	Domain name	Owner	Expiry date
1.	biosunpharma.com	The Company	April 4, 2027

C. FURTHER INFORMATION ABOUT OUR DIRECTORS AND SUBSTANTIAL SHAREHOLDERS

1. Particulars of Directors’ Service Contracts

We [have] entered into a service contract with each of our Directors which contains provisions in relation to, among others, term of service and termination. The service contracts may be renewed in accordance with our Articles of Association and the applicable rules.

Save as disclosed in “Directors and Senior Management” and above, we have not entered into, and do not propose to enter into, any service contracts with any of our Directors in their respective capacities as Directors (excluding agreements expiring or determinable by any member of our Group within one year without payment of compensation other than statutory compensation).

2. Remuneration of Directors

Save as disclosed in “Directors and Senior Management” and “Appendix I — Accountants’ Report — II. Notes to the Historical Financial Information — 9,” none of our Directors received other remuneration or benefits in kind from our Company during the Track Record Period.

APPENDIX VII STATUTORY AND GENERAL INFORMATION

3. Disclosure of Interests

(a) Interests of our Directors and chief executive of the Company

Save as disclosed below, immediately following the completion of the [REDACTED] (assuming no exercise of the [REDACTED]) and the conversion of the Domestic Shares into H Shares, so far as the Directors are aware, none of the Directors or chief executive of the Company will have any interest and/or short position (as applicable) in the Shares, underlying Shares or debentures of the Company or our associated corporation (within the meaning of Part XV of the SFO) which will be required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they are taken or deemed to have under such provisions of the SFO) or which will be required, pursuant to Section 352 of the SFO, to be entered in the register referred to therein, or which will be required, pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules to be notified to the Company and the Stock Exchange, once the H Shares are [REDACTED] on the Stock Exchange.

(i) Interests in the Shares

Name	Position	Nature of interest	Number and description of Shares held	Approximate percentage of shareholding in the relevant type of Shares	Approximate percentage of shareholding in the total share capital of the Company
Mr. Li Bangliang (李邦良)	Chairman of the Board, executive Director	Interested in the controlled corporation ⁽¹⁾	[REDACTED] H Shares	[REDACTED]%	[REDACTED]%
Dr. Lyu Yubin (吕裕斌)	Executive Director, general manager	Interested in the controlled corporation ⁽²⁾	[REDACTED] H Shares	[REDACTED]%	[REDACTED]%
Mr. Li Yuedong (李閱東)	Executive Director, deputy general manager	Interested in the controlled corporation ⁽³⁾	[REDACTED] H Shares	[REDACTED]%	[REDACTED]%

Notes:

- (1) As of the Latest Practicable Date, Mr. Li Bangliang owned 99.0% of the equity interest in Hangzhou Wanyuhe and 80.0% of the partnership interest in Hangzhou Sanrui as its general partner. In addition, Mr. Li is the general partner of Hangzhou Liuyintai. Accordingly, Mr. Li Bangliang is deemed to be interested in an aggregate of 15,885,000 Shares held by Hangzhou Wanyuhe, Hangzhou Sanrui and Hangzhou Liuyintai under the SFO.
- (2) As of the Latest Practicable Date, Dr. Lyu Yubin owned approximately 67.2% of the equity interest in Hangzhou Jiuyin. Accordingly, Dr. Lyu Yubin is deemed to be interested in the 14,115,000 Shares held by Hangzhou Jiuyin under the SFO.
- (3) As of the Latest Practicable Date, Mr. Li Yuedong, as a limited partner, owned 82.02% of the partnership interest in Hangzhou Liuyintai. Accordingly, Mr. Li Yuedong is deemed to be interested in the 2,385,000 Shares held by Hangzhou Liuyintai under the SFO.

Save as disclosed in “Substantial Shareholders” in this document, the Directors are not aware of any other person (other than the Directors or chief executive of the Company) who will, immediately following the completion of the [REDACTED] (assuming no exercise of the [REDACTED]) and the conversion of the Domestic Shares into H Shares, have an interest and/or short position in the Shares or underlying Shares which would fall to be disclosed to the Company

APPENDIX VII

STATUTORY AND GENERAL INFORMATION

and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or who is, directly or indirectly, interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of the Company or any other member of the Group.

4. Agency Fees or [REDACTED] Received

The [REDACTED] will receive an [REDACTED] in connection with the [REDACTED]. See “[REDACTED].” Save in connection with the [REDACTED], no [REDACTED], discounts, brokerages or other special terms have been granted by the Group to any person (including the Directors, promoters and experts referred to in “— D. Other Information — 6. Qualifications of Experts” below) in connection with the issue or sale of any capital or security of the Company or any member of the Group within the two years immediately preceding the date of this document.

Within the two years immediately preceding the date of this document, no [REDACTED] has been paid or is payable for subscription, agreeing to subscribe, procuring subscription or agreeing to procure subscription for any shares in or debentures of the Company.

5. Disclaimers

- (a) Save as disclosed in “History, Development and Corporate Structure” above, none of our Directors or experts named in “— 6. Qualifications of Experts” in this section is interested in our promotion, or in any assets which have been, within the two years immediately preceding the issue of this document, acquired or disposed of by or leased to any member of our Group, or are proposed to be acquired or disposed of by or leased to any member of our Group;
- (b) Save in connection with the [REDACTED], none of our Directors is materially interested in any contract or arrangement subsisting at the date of this document which is significant in relation to the business of our Group;
- (c) none of our Directors or their respective close associates or our Shareholders which to the knowledge of our Directors own more than 5% of the number of our issued Shares (excluding treasury shares) has any interest in our five largest customers or suppliers during the Track Record Period; and
- (d) except that (i) Mr. Li Bangliang is the general partner of Hangzhou Sanrui, and (ii) Dr. Lyu Yubin is a director of Hangzhou Jiuyin, none of our Directors is a director or employee of a company which has an interest or short position in the Shares or underlying Shares of our Company which would fall to be disclosed to our Company pursuant to Divisions 2 and 3 of Part XV of the SFO.

D. OTHER INFORMATION

1. Estate Duty

Our Directors have been advised that no material liability for estate duty is likely to fall on our Company or our subsidiaries.

2. Litigation

As of the Latest Practicable Date, no member of our Group was involved in any litigation, arbitration, administrative proceedings or claims of material importance, and, so far as we are aware, no litigation, arbitration, administrative proceedings or claims of material importance are pending or threatened against any member of our Group.

APPENDIX VII

STATUTORY AND GENERAL INFORMATION

3. Sole Sponsor

The Sole Sponsor has made an application on behalf of our Company to the Stock Exchange for the [REDACTED] of, and permission to [REDACTED], the H Shares to be issued pursuant to the [REDACTED] and the H Shares to be converted from Domestic Shares, on the Main Board of the Stock Exchange. The Sole Sponsor will receive an aggregate fee of US\$0.6 million for acting as sole sponsor for the [REDACTED].

The Sole Sponsor satisfies the independence criteria applicable to sponsor set out in Rule 3A.07 of the Listing Rules.

4. Preliminary Expense

The Company did not incur any material preliminary expenses.

5. Promoters

The promoters of the Company are all then 31 shareholders of the Company as of October 18, 2025 before our conversion into a joint stock company with limited liability. Within the two years immediately preceding the date of this document, no cash, securities or other benefit has been paid, allotted or given nor are any proposed to be paid, allotted or given to any promoters in connection with the [REDACTED] or the related transactions described in this document.

6. Qualifications of Experts

The qualifications of the experts who have given opinions or advice in this document are as follows:

Name	Qualification
China Securities (International) Corporate Finance Company Limited	Licensed to conduct Type 1 (dealing in securities) and Type 6 (advising on corporate finance) of regulated activities as defined under the SFO
Ernst & Young	Certified Public Accountants and Registered Public Interest Entity Auditor under the Accounting and Financial Reporting Council Ordinance
Zhejiang T&C Law Firm	Legal advisor to our Company as to PRC law
Hiways Law Firm	Legal advisor to our Company as to intellectual property law of the PRC
Allbright Law Offices	Legal advisor to our Company as to data compliance law of the PRC
Frost & Sullivan	Independent industry consultant
Jones Lang LaSalle Corporate Appraisal and Advisory Limited	Independent property valuer

7. Consent of Experts

Each of the experts named above has given and has not withdrawn its written consent to the issue of this document with the inclusion of its reports, letters or opinions (as the case may be) and the references to its name included herein in the form and context in which they are included.

APPENDIX VII

STATUTORY AND GENERAL INFORMATION

As of the Latest Practicable Date, none of the experts named above had any shareholding in any member of our Group or right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of our Group.

8. Stamp Duty

The sale, purchase and transfer of H Shares will be subject to Hong Kong stamp duty. The current rate charged on each of the seller and purchaser is 0.1% of the consideration or, if higher, the fair value of the H Shares being sold or transferred.

9. Binding Effect

This document shall have the effect, if any application is made pursuant hereto, of rendering all persons concerned bound by all the provisions (other than the penal provisions) of sections 44A and 44B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance as far as applicable.

10. Bilingual Document

The English language and Chinese language versions of this document are being published separately in reliance upon the exemption provided by section 4 of the Companies Ordinance (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong).

11. Miscellaneous

- (a) Within the two years immediately preceding the issue of this document, no share or debenture of any member of our Group has been issued or agreed to be issued or is proposed to be issued for cash or as fully or partly paid up otherwise than in cash.
- (b) Within the two years immediately preceding the issue of this document, no share or debenture of any member of our Group is under option or agreed conditionally or unconditionally to be put under option.
- (c) There are no founder or management or deferred shares in our Company.
- (d) There is no restriction affecting the remittance of profits or repatriation of capital of our Company into Hong Kong from outside Hong Kong.
- (e) There is no arrangement under which future dividends are waived or agreed to be waived.
- (f) There are no contracts for the hire or hire purchase of plant to or by our Group for a period of over one year which are substantial in relation to our Group’s business.
- (g) There have been no interruptions in our business which may have or have had a significant effect on our financial position in the last 12 months.
- (h) No part of the equity or debt securities of our Company is [REDACTED] or [REDACTED] in on any stock exchange, and no such [REDACTED] or permission to [REDACTED] on any stock exchange other than the Stock Exchange is being or is proposed to be sought.
- (i) Our Company has no outstanding convertible debt securities or debentures.